Pyxis Oncology’s IPO raised $168 million as the biotech steers toward the clinic with drug candidates and technology licensed from Pfizer. Theseus Pharma, IsoPlexis, and Cognition Therapeutics also went public; combined the four companies raised nearly half a billion dollars.
Neurodegenerative disorders drug developer Cognition Therapeutics has raised $1.8 million in equity, according to a regulatory filing. The Pittsburgh-based company is developing multiple drug candidates to treat Alzheimer’s disease and similar central nervous system disorders. The latest fundraise is the first close of what’s hoped to be a $3 million series A2 round, CEO Hank […]
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
The challenge of identifying and establishing financing for early and mid-stage companies is forcing companies to be more creative and making the series of panel discussions on the subject at Biotech 2011 in Philadelphia a high priority as companies and investors fleshed out what some of those structures look like. “Funding is patchwork,” said Al […]
Neurodegenerative disorders drug developer Cognition Therapeutics has raised $2.5 million in a Series A1 round of investment. The funding will support preclinical research, as the company investigates which of its drug candidates to pursue.
Cognition Therapeutics focuses on detecting Abeta proteins, a protein found in Alzheimer's patients that leads to the degeneration in the brain. The company is also developing molecules to block the proteins' negative results and either stop or reverse Alzheimer's. The company says its discoveries could also treat other neurodegenerative diseases.